ABT-555

DRUG2 trials

Sponsors

AbbVie

Conditions

Multiple Sclerosis

Phase 1

A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis

CompletedNCT02601885

AbbVieMultiple Sclerosis

Start: 2016-10-18End: 2018-04-20Updated: 2018-05-17

[11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis

TerminatedNCT02606630

AbbVieMultiple Sclerosis

Start: 2015-10-31End: 2015-12-31Updated: 2017-02-08

Related Papers

Phase 1 Evaluation of Elezanumab (<scp>Anti–Repulsive Guidance Molecule A</scp> Monoclonal Antibody) in Healthy and Multiple Sclerosis Participants

Annals of Neurology2022-09-1222 citations